Gencurix Inc.

A229000

KR7229000005

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-21 EDT			5-day change	1st Jan Change
3,115 ^KRW	+1.47%		-2.66%	-49.92%

04-15	J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. from Gencurix Inc. for KRW 3 billion.	CI
04-03	J&L Agent Co., Ltd. and other buyer agreed to acquire 4.97% stake in NGeneBio Co., Ltd. from Gencurix Inc. for KRW 3.2 billion.	CI

Gencurix Inc. announced that it has received KRW 4.0000215 billion in funding from Korea Investment Partners Co. Ltd., KDB Capital Corporation, Investment Arm

January 30, 2020

On January 31, 2020, Gencurix Inc. (XKON:A229000) closed the transaction.

Latest news about Gencurix Inc.

J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. from Gencurix Inc. for KRW 3 billion.	04-14	CI
J&L Agent Co., Ltd. and other buyer agreed to acquire 4.97% stake in NGeneBio Co., Ltd. from Gencurix Inc. for KRW 3.2 billion.	04-02	CI
Gencurix Inc. announced that it has received KRW 3.99999552 billion in funding from HLB PANAGENE Co., LTD.	01-24	CI
HLB PANAGENE Co., LTD. announced that it has received KRW 2 billion in funding from Gencurix Inc.	01-23	CI
HLB PANAGENE Co., LTD. announced that it expects to receive KRW 2 billion in funding from Gencurix Inc.	01-16	CI
Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.	12-27	CI
Abion Inc. announced that it expects to receive KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.	12-19	CI
Gencurix Inc. Obtains Approval for Companion Diagnostic of Digital Pcr-Based Egfr Mutation Test	23-06-13	CI
Gencurix Announces Clinical Research Results at Asco Demonstrating Outstanding Performance of GenesWellBCT Compared to Global Best-Selling Test, Oncotypedx	23-06-07	CI
Gencurix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Gencurix Announces Korean and Japanese Cancer Patients' 15-Year Follow-Up Prognostic Test Clinical Results	23-05-09	CI
Gencurix to Raise 28 Billion Won From Stock Offering	23-01-17	MT
Gencurix Inc. announced that it has received KRW 26.9999819 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, Aju IB Investment Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm and other investors	21-06-07	CI
Gencurix Inc. announced that it expects to receive KRW 26.9999819 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, Aju IB Investment Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm and other investors	21-05-30	CI
Gencurix Inc. announced that it has received KRW 2 billion in funding	20-08-30	CI
Gencurix Inc. announced that it expects to receive KRW 2 billion in funding	20-08-20	CI
Gencurix Inc. agreed to acquire a 41% stake in Nano Bio Life Co., Ltd. from Soo-kyung Kim, Jihye Cheon, Injoong Kim, Ki-moon Song, Jichul Hyun and Sujin Lee for KRW 3.7 billion.	20-08-20	CI
Gencurix Inc. Receives U.S. Food and Drug Administration's Emergency Use Authorization for Its GenePro SARS-CoV-2 Test	20-06-24	CI
Gencurix to Release New Coronavirus Diagnostic Kit in the EU	20-03-20	CI
Gencurix Inc. announced that it has received KRW 1.299999 billion in funding from AJU Capital Co., Ltd., Samsung Securities Co. Ltd., Investment Arm	20-02-10	CI
Gencurix Inc. announced that it expects to receive KRW 1.299999 billion in funding from AJU Capital Co., Ltd., Samsung Securities Co. Ltd., Investment Arm	20-02-09	CI
Gencurix Inc. announced that it has received KRW 4.0000215 billion in funding from Korea Investment Partners Co. Ltd., KDB Capital Corporation, Investment Arm	20-01-30	CI
Gencurix Inc. announced that it expects to receive KRW 4.0000215 billion in funding from Korea Investment Partners Co. Ltd., KDB Capital Corporation, Investment Arm	20-01-27	CI
Gencurix, Inc. Announces the First Comparison Data between GenesWell BCT and Oncotype DX	19-08-13	CI
Gencurix Announces Further Evidences for GenesWell™ BCT	18-12-05	CI

Gencurix Inc. is a Korea-based company mainly engaged in the sale of medical equipments. In addition, the Company is involved in the manufacturing and sale of breast cancer test (BCT) kits, Korean genetic polymorphism diagnostic kits, lung cancer and colorectal cancer diagnostic kits. The BCT kits are used for analyzing the expression level of the cancer-related gene. The products are sold under the name of GenesWell.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-23 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
GENCURIX INC.	-49.92%	32.53M
BIOMÉRIEUX	-6.16%	12.1B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.26%	8.16B
DIASORIN S.P.A.	+6.61%	5.78B
LANTHEUS HOLDINGS, INC.	+31.20%	5.59B
AUTOBIO DIAGNOSTICS CO., LTD.	-9.05%	4.23B
10X GENOMICS, INC.	-56.99%	2.87B
ANDON HEALTH CO., LTD.	+11.87%	2.71B
VITROLIFE AB	-5.34%	2.35B
MYRIAD GENETICS, INC.	+25.34%	2.21B